Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively

MLA

Hong Tao, et al. “Concomitant Novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK Double-Fusion Variants and Confer Sensitivity to Crizotinib in Two Lung Adenocarcinoma Patients, Respectively.” Diagnostic Pathology, vol. 17, no. 1, Feb. 2022, pp. 1–7. EBSCOhost, https://doi.org/10.1186/s13000-022-01212-9.

APA

Hong Tao, Zhe Liu, Jing Mu, Fei Gai, Zhan Huang, & Liang Shi. (2022). Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively. Diagnostic Pathology, 17(1), 1–7. https://doi.org/10.1186/s13000-022-01212-9

Chicago

Hong Tao, Zhe Liu, Jing Mu, Fei Gai, Zhan Huang, and Liang Shi. 2022. “Concomitant Novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK Double-Fusion Variants and Confer Sensitivity to Crizotinib in Two Lung Adenocarcinoma Patients, Respectively.” Diagnostic Pathology 17 (1): 1–7. doi:10.1186/s13000-022-01212-9.